sunitinib
Selected indexed studies
- Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. (Drug Resist Updat, 2023) [PMID:36739809]
- Sunitinib-induced thrombotic microangiopathy. (J Cancer Res Ther, 2016) [PMID:27072203]
- Sunitinib in the Treatment of Thyroid Cancer. (Curr Med Chem, 2019) [PMID:28990511]
_Worker-drafted node — pending editorial review._
Connections
sunitinib is a side effect of
Sources
- Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. (2023) pubmed
- Sunitinib-induced thrombotic microangiopathy. (2016) pubmed
- Sunitinib in the Treatment of Thyroid Cancer. (2019) pubmed
- Sunitinib. (2006) pubmed
- AIM2 promotes renal cell carcinoma progression and sunitinib resistance through FOXO3a-ACSL4 axis-regulated ferroptosis. (2023) pubmed
- N(6)-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma. (2022) pubmed
- MTHFD2 Enhances cMYC O-GlcNAcylation to Promote Sunitinib Resistance in Renal Cell Carcinoma. (2025) pubmed
- Sunitinib and its effect in the cardiovascular system. (2021) pubmed
- Sunitinib in solid tumors. (2009) pubmed
- Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics. (2023) pubmed